Literature DB >> 21965875

Liquid formulation of minoxidil versus its foam formulation.

Tugrul Purnak1, Engin Senel, Ceren Sahin.   

Abstract

Entities:  

Year:  2011        PMID: 21965875      PMCID: PMC3179030          DOI: 10.4103/0019-5154.84714

Source DB:  PubMed          Journal:  Indian J Dermatol        ISSN: 0019-5154            Impact factor:   1.494


× No keyword cloud information.
Sir, Various treatment modalities for androgenetic alopecia have been developed in recent years. Currently, there are several effective medications to treat androgenetic alopecia, including minoxidil and finasteride. Minoxidil was first used as a anti hypertensive agent for refractory hypertension. It acts selectively on potassium channels and creates a vasodilatator effect on arterioles. The mechanism of action of this drug on hair growth is still unknown. Topical minoxidil shortens the telogen phase and causes premature entry of resting hair follicles into anagen; this effect may be valid for human hair follicles.[1] Since unexpected hair growth was noted as an adverse reaction during its oral ingestion for hypertension, meticulous efforts to obtain a local effect on scalp began in the early 1980s. Topical form of minoxidil has been used since 1984 for androgenetic alopecia. Minoxidil sulfate is metabolized by sulfotransferase present in the scalp and is the active form of minoxidil molecule.[2] Although the exact mechanism remains poorly understood, several theories have been proposed. The most accepted mechanism is related to the vasodilatator effect of the molecule. Increased blood flow to the scalp may stimulate hair growth. Other mechanisms are focused on hair follicle proliferation, which is boosted by minoxidil.[3] In this concept, minoxidil might be thought to be similar to epidermal growth factor.[4] There are two main forms of topical minoxidil molecule. One is the liquid formulation and the other is the foam formulation. Both formulations are subcategorized on the basis of their minoxidil content, such as 2% minoxidil (Minoxidil regular strength form) or 5% minoxidil (Minoxidil extra strength form). It has been proved that 2% minoxidil was less effective than 5% minoxidil in producing the desired result.[5] The liquid formulation contains propylene glycol, water, and alcohol. Propylene glycol is needed as a vehicle to solve minoxidil. However, most of the adverse reactions are related to hypersensitivity of propylene glycol. Itching, contact dermatitis and squamation of the scalp are attributed to propylene glycol content of topical minoxidil solution.[6] With these aesthetic concerns, the topical foam of minoxidil was developed, which is propylene glycol-free. In the literature, there is no comparative study between the two formulations in humans.[7] In an animal study, the foam formulation was found as effective as the liquid formulation.[8] It is a fact that the stratum corneum functions as a barrier for skin absorption and abraded or eczematized skin is a weak skin barrier, which leads to enhanced absorption of topical medications. In a study conducted by Wester et al., 5% topical liquid form of minoxidil was observed to cause the greatest increase in the cutaneous blood flow by using Doppler velocimetry and photopulse plethysmography comparing to 1% and 3% topical liquid form of minoxidil. This finding suggested that increasing minoxidil concentration correlates with increasing hair growth.[3] In conclusion, the new alternative for topical minoxidil in the form of foam is effective from cosmetic point of view. Although contact dermatitis side effect of topical minoxidil liquid form is disturbing for many patients cosmetically, it is possible that the liquid form has a better absorption because of the epidermal disturbance due to contact dermatitis. However, this question remains unresolved until further human studies are initiated.
  8 in total

1.  Rapid determination of trace amounts of minoxidil in hamster skin follicles with various formulations using narrow-bore LC/EC.

Authors:  Tiehua Huang; Michelle E Garceau; Tore Ramstad; Randall G Stehle
Journal:  J Pharm Biomed Anal       Date:  2005-03-19       Impact factor: 3.935

2.  A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.

Authors:  Elise A Olsen; David Whiting; Wilma Bergfeld; Jeffrey Miller; Maria Hordinsky; Rita Wanser; Paul Zhang; Bruce Kohut
Journal:  J Am Acad Dermatol       Date:  2007-08-29       Impact factor: 11.527

3.  Allergic contact dermatitis to topical minoxidil solution: etiology and treatment.

Authors:  Edward S Friedman; Paul M Friedman; David E Cohen; Ken Washenik
Journal:  J Am Acad Dermatol       Date:  2002-02       Impact factor: 11.527

4.  Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography.

Authors:  R C Wester; H I Maibach; R H Guy; E Novak
Journal:  J Invest Dermatol       Date:  1984-05       Impact factor: 8.551

Review 5.  Medical treatments for male and female pattern hair loss.

Authors:  Nicole E Rogers; Marc R Avram
Journal:  J Am Acad Dermatol       Date:  2008-10       Impact factor: 11.527

6.  Minoxidil sulfation in the hair follicle.

Authors:  C A Baker; H Uno; G A Johnson
Journal:  Skin Pharmacol       Date:  1994

Review 7.  Minoxidil: mechanisms of action on hair growth.

Authors:  A G Messenger; J Rundegren
Journal:  Br J Dermatol       Date:  2004-02       Impact factor: 9.302

8.  A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.

Authors:  Elise A Olsen; Frank E Dunlap; Toni Funicella; Judith A Koperski; James M Swinehart; Eduardo H Tschen; Ronald J Trancik
Journal:  J Am Acad Dermatol       Date:  2002-09       Impact factor: 11.527

  8 in total
  2 in total

1.  Preparation and evaluation of minoxidil foamable emu oil emulsion.

Authors:  M A Shatalebi; Y Rafiei
Journal:  Res Pharm Sci       Date:  2014 Mar-Apr

Review 2.  Minoxidil and its use in hair disorders: a review.

Authors:  Poonkiat Suchonwanit; Sasima Thammarucha; Kanchana Leerunyakul
Journal:  Drug Des Devel Ther       Date:  2019-08-09       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.